Gilead Sciences, Inc.  

(Public, NASDAQ:GILD)   Watch this stock  
Find more results for GILD
82.64
+0.35 (0.43%)
After Hours: 82.52 -0.12 (-0.15%)
Sep 20, 7:59PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 81.84 - 82.90
52 week 63.76 - 86.27
Open 82.36
Vol / Avg. 0.00/10.48M
Mkt cap 107.92B
P/E 8.97
Div/yield 0.52/2.52
EPS 9.21
Shares 1.31B
Beta 1.19
Inst. own 77%
Oct 30, 2017
Q3 2017 Gilead Sciences Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Sep 11, 2017
Gilead Sciences Inc at Morgan Stanley Healthcare Conference - Webcast
Sep 6, 2017
Gilead Sciences Inc at Citi Biotech Conference - Webcast
Aug 28, 2017
Gilead Sciences Inc to Acquire Kite Pharma Inc Conference Call - Webcast
Jul 26, 2017
Q2 2017 Gilead Sciences Inc Earnings Call - Webcast
Jul 26, 2017
Q2 2017 Gilead Sciences Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin 42.98% 44.38%
Operating margin 59.57% 58.02%
EBITD margin - 64.57%
Return on average assets 20.87% 24.82%
Return on average equity 57.17% 72.16%
Employees 9,000 -
CDP Score - -

Address

333 LAKESIDE DR
FOSTER CITY, CA 94404
United States - Map
+1-650-5743000 (Phone)
+1-650-5789264 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha

Description

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.

Officers and directors

John C. Martin Ph.D. Executive Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
John F. Milligan Ph.D. Chief Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters
Robin L. Washington Chief Financial Officer, Executive Vice President
Age: 54
Bio & Compensation  - Reuters
Kevin B. Young Chief Operating Officer
Age: 59
Bio & Compensation  - Reuters
Norbert W. Bischofberger Ph.D. Executive Vice President - Research and Development, Chief Scientific Officer
Age: 61
Bio & Compensation  - Reuters
Gregg H. Alton Executive Vice President - Corporate and Medical Affairs
Age: 51
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
James R. Meyers Executive Vice President - Worldwide Commercial Operations
Age: 52
Bio & Compensation  - Reuters
John F. Cogan Jr. Ph.D. Lead Independent Director
Age: 69
Bio & Compensation  - Reuters
Kelly A. Kramer Independent Director
Age: 49
Bio & Compensation  - Reuters
Kevin E. Lofton Independent Director
Age: 62
Bio & Compensation  - Reuters